Effects of Yinzhihuang Granules on Serum Liver Enzymes in Jaundice Patients: A Real-World Study Based on HIS Data

Cheng Zhang  
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital of Skin Diseases and Institute of Dermatology  
https://orcid.org/0000-0003-3851-9943

Lidan Zhang  
China Academy of Chinese Medical Sciences

Jian Lyu  
China Academy of Chinese Medical Sciences

Yanming Xie  
ktzu2018@163.com  
China Academy of Chinese Medical Sciences

Yuting Xie  
Renmin University of China

Research

Keywords: yinzhihuang granules, jaundice, liver enzyme indicators, real-world studies, hospital information system

DOI: https://doi.org/10.21203/rs.3.rs-34058/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background**: *Yinzhihuang* granule is a proprietary Chinese medicine to treat jaundice. The formula was derived from *Yinchenhao decoction* in Zhongjing Zhang’s “Treatise on Febrile Diseases,” which has been used to treat jaundice for more than two thousand years. *Yinzhihuang* granule has been widely used in China to treat neonatal jaundice; its effectiveness has been confirmed by randomized controlled trials, but there have been only few real-world studies. Electronic medical record is an important source of data for the real-world studies. We previously constructed a data warehouse which integrates real-world electronic medical records from the hospital information system of multiple 3A hospitals in China and then performed a series of beneficial real-world exploratory researches. Our aim was to analyze the influence of *yinzhihuang* granule on serum liver enzymes in jaundice patients and to provide real-world evidence for the efficacy evaluation of *yinzhihuang* granule in treating jaundice.

**Methods**: We used a descriptive statistical method to analyze the changes in the serum liver enzymes of the jaundice patients treated with *yinzhihuang* granules and then used Wilcoxon signed-rank to test the changes in the indicators caused by the treatment.

**Results**: After being treated with *yinzhihuang* granules, the jaundice patients had a decrease in the average serum levels of total bilirubin, indirect bilirubin, aspartate aminotransferase, glutamyl transpeptidase, alkaline phosphatase, and the differences were statistically significant (*P* < 0.05), but had no significant changes in the average serum levels of direct bilirubin and alanine aminotransferase (*P* > 0.05).

**Conclusion**: The data analysis on the real-world electronic medical records demonstrate that *yinzhihuang* granules help to reduce jaundice patients’ serum levels of total bilirubin, indirect bilirubin, aspartate aminotransferase, glutamyl transpeptidase, alkaline phosphatase, but there is no evidence that *yinzhihuang* granules help to reduce the jaundice patients’ serum levels of direct bilirubin and alanine aminotransferase.

**Background**

Jaundice, the yellow staining of skin, sclera, and mucous membrane caused by the elevation of bilirubin, is a common indicator of hepatobiliary diseases [1]. Jaundice occurs when the plasma bilirubin is excessive or when the damaged liver fails to clear bodily bilirubin [2]. In addition to yellow skin, jaundice patients may suffer from stomachache, nausea, fever, weight loss, or itching [3]. The disease should be treated differently in accordance with the different disease etiology, but the general principle is “to remove jaundice, protect liver, reduce enzyme.” With the verified effectiveness and very few adverse reactions reported, the traditional Chinese medicine (TCM) has certain advantages in treating jaundice. According to TCM, jaundice is a common clinical syndrome primarily indicated by yellow skin, yellow eye, and yellow urine [4] and has multiple different pathogenesis such as dampness, heat, cold, blood stasis, and spleen deficiency, with pathogenic dampness being the dominant one; thus, the treatment should be...
based on syndrome differentiation. For the patients with damp-heat brewing internally, Zhongjing Zhang wrote in “Treatise on Febrile Diseases” that *Yinchenhao decoction* can be used to treat them [5].

*Yinzhihuang* granule, derived from *Yinchenhao decoction*, is a proprietary Chinese medicine to treat jaundice. Its ingredients are extracted from *Artemisiae Scopariae Herba*, *Gardeniae Fructus*, *Scutellariae Radix*, and *Lonicerae Japonicae Flos*. According to the drug package insert records, it is effective in clearing heat and detoxifying and clearing dampness and removing jaundice. It can be used to treat jaundice caused by liver-gallbladder dampness-heat with the symptoms of yellow skin and eye, chest pain, nausea and vomiting, reddish yellow urine and the acute or chronic hepatitis with the aforementioned syndromes.

At present, the evaluation of effectiveness of *yinzhihuang* granules on jaundice is based primarily on randomized controlled trials; for example, the latest systematic review included nine randomized controlled trials [6]. The evaluation demonstrated that the blue light treatment of neonatal pathologic jaundice, when combined with *yinzhihuang* granules administration, was better than the sole blue light treatment, in terms of both clinical effective rate and jaundice fading time (*P* < 0.05). In terms of safety studies, no serious adverse reactions have been reported in the literature, but the instructions of *yinzhihuang* granule indicate that there are reports of diarrhea, vomiting, and rash.

The elevation of serum liver enzyme levels is common in liver diseases; the abnormalities of liver enzyme indicators are associated with the possible etiology of liver disease. The enzymes that are commonly detected include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), and serum bilirubin [7]. These liver enzymes are not only important diagnosis biomarkers but also important indicators of curative effects on, and prognosis of, jaundice. The elevation of serum bilirubin levels is the direct cause of jaundice [8]. ALT, present in high concentrations in hepatocyte cytoplasm, is very sensitive to hepatocyte injury and is the most specific traditional biomarker. AST, also present in hepatocytes, can be used to determine whether or not jaundice is caused by liver injury [9], but its liver specificity is relatively low [10]. The elevation of ALP and GGT levels indicate cholestasis. In jaundice patients, the elevation of ALP levels can be used to diagnose obstructive jaundice because it may indicate diffuse hepatocyte dysfunction or severe bile duct obstruction, which obstructs the adequate bile flow [11].

Unlike the traditional randomized controlled trial performed under strict conditions, the real-world study, which can evaluate the actual drug efficacy, is based on the actual medical environment. We performed a retrospective study of hospital electronic medical record data, analyzed the changes in the serum liver enzyme indicators caused by *yinzhihuang* granule intervention, and provided the real-world evidences to support *yinzhihuang* granule in treating jaundice.

### Methods

#### Data source and normalization
The data we used were taken from a large-scale data warehouse where electronic medical records are integrated and which was constructed, on the basis of Chinese 3A hospital information system (HIS), by Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences[12]. From the warehouse, we extracted the data of 3610 jaundice patients who had been treated with *yinzhihuang* granules and who met the jaundice diagnosis standard: serum total bilirubin (TBil) > 17.1 μmol/L (namely, 1.0 mg/dl) [13]. Their laboratory test information was extracted and analyzed, including seven serum liver enzyme indicators: TBil, direct bilirubin (DBil), indirect bilirubin (IBil), ALT, AST, GGT, and ALP.

Because the data used were from different hospitals in the country and they might adopt different standards for the same project, the investigators, to facilitate analysis [14], normalized the data by converting the units of TBil, DBil and IBil from mg/dl to μmol/L, which entailed multiplying the value by 17.1 [13].

**Inclusion and exclusion criteria**

The jaundice patients from the HIS database who met the following criteria were included in our study: (1) they were treated with *yinzhihuang* granules; (2) their TBil values were greater than 17.1 μmol/L (1.0mg/dl) for at least one test; (3) there were at least one detection of serum liver enzymes seven days before and seven days after the use of *yinzhihuang* granules. On the other hand, those jaundice patients were excluded from the study whose serum liver enzyme detections before and after the medication were both absent.

**Data definition and outcome determination**

For every included patient, two sets of liver enzyme data were extracted: one set was obtained within seven days before *yinzhihuang* granule treatment and the other set was obtained within seven days after the medication withdrawal. If there were more than one set of data satisfying the condition, then the latest one within seven days before the treatment was defined to be “pre-medication physicochemical indicator” and the earliest one within seven days after the medication withdrawal was defined to be “post-medication physicochemical indicator” [15].

The criteria for liver enzyme abnormality were based on each hospital’s respective physicochemical reference value. A liver enzyme indicator is abnormal if it is above the upper bound of the normal values. No matter whether the pre-medication indicators were normal or not, as long as the post-medication indicators were normal, the patient was recorded as “post-medication normal changes.” If both the pre- and post-medication indicators were abnormal but the degree of abnormality decreased after the medication, then the patient was also recorded as “post-medication normal changes.” If the patient was normal before medication but abnormal after the medication, or abnormal before the medication and more abnormal after the medication, then the patient was recorded as “post-medication abnormal changes” [16].
Statistical analysis methods and software

All the data analyses were performed by the software SAS 9.4. We did the descriptive statistics and quantitative analysis on the general data of the jaundice patients’ serum liver enzymes tested before and after the medication. For the normally distributed variables, the mean, standard deviation, median value, maximum value, and minimum value were obtained. For the non-normally distributed variables, the median value, interquartile range, maximum value, and minimum value were obtained. Qualitative analysis was performed on the normal/abnormal changes of the jaundice patients’ liver enzymes caused by the medication; namely, the post-medication liver enzyme values were compared to the pre-medication liver enzyme values. When the difference between the two datasets followed the normal distribution, it was tested by paired sample \( t \) test. When the difference did not follow the normal distribution, it was tested by non-parametric test (Wilcoxon signed-rank). \( P < 0.05 \) was considered statistically significant.

Results

The characteristics of the jaundice patients

The demographic and clinical characteristics of the 3610 patients with jaundice are shown in Table 1. Among the patients, 68.67% were male and approximately 50% were older than 45. The patients had an average age of 39.33 (median: 45). For the treatment, the average single dose was 5.66 g (median: 6) and the average duration was 6.62 days (median: 4).
| Characteristic                              | Population |
|--------------------------------------------|------------|
| Gender                                     | 2479       |
| Male                                       | 2479       |
| Female                                     | 1087       |
| Missing                                    | 44         |
| Age                                        |            |
| <=12yr                                     | 760        |
| (12-18]yr                                  | 54         |
| (18-45]yr                                  | 1029       |
| (45-65]yr                                  | 1242       |
| (65-85]yr                                  | 507        |
| 85yr                                       | 16         |
| Hospitalization time                       |            |
| <=3d                                       | 242        |
| (3-7]d                                     | 491        |
| (7-14]d                                    | 831        |
| (14-28]d                                   | 1065       |
| Missing                                    | 67         |
| Western medicine diagnosis\(^a\)          |            |
| Neonatal hyperbilirubinemia                | 238        |
| Pulmonary tuberculosis                     | 170        |
| Chronic active hepatitis B                 | 79         |
| TCM syndrome\(^b\)                         |            |
| Damp-heat                                  | 67         |
| Condition                              | Code |
|----------------------------------------|------|
| Deficiency of both qi and blood        | 32   |
| Yang qi deficiency                     | 32   |

| Dose Range   | Code |
|--------------|------|
| ≤6g          | 3337 |
| (6-12]g      | 47   |
| (12-18]g     | 16   |
| (18-30]g     | 37   |
| (30-60]g     | 23   |
| ≥60g         | 20   |
| Missing      | 6    |

| Treatment Duration | Code |
|--------------------|------|
| ≤3d                | 1269 |
| [4-7]d             | 567  |
| [8-14]d            | 530  |
| [15-28]d           | 432  |
| Missing            | 649  |

| Combined Use of Drugs | Code |
|-----------------------|------|
| TCM© Ganmao Qingre granules | 416  |
| TCM© Kuhuang injection  | 382  |
| TCM© Bupleurum injection | 360  |

Western medicine: 1831
Table 1
The demographic and clinical characteristics of the jaundice patients

| Glycyrrhizic acid | Western medicine: Thymosin | 1028 |
| Western medicine: Dexamethasone | 592 |

Table 1, a, b, c the top three in Population.

Description and analysis of the liver enzyme indicators before and after the medication

We respectively described and analyzed the general data of the jaundice patients’ liver enzymes tested before medication (Table 2) and after (Table 3). We compared the jaundice patients’ post-medication liver enzyme data boxplot with the pre-medication boxplot (Figs. 1-7) and found that, while the average levels of TBil, IBil, AST, GGT, and ALP decreased after the medication, the average levels of DBil and ALT did not change significantly. In the figures, the middle line represents the average level of the liver enzyme analyzed.
| Variable | Number of cases | Median | Lower quartile | Interquartile range | Upper quartile | Minimum | Maximum |
|----------|----------------|--------|----------------|---------------------|----------------|---------|---------|
| TBil (μmol/L) | 952 | 79 | 35.5 | 169.8 | 205.3 | 12 | 609.6 |
| DBil (μmol/L) | 1027 | 16.9 | 9 | 37 | 46 | 0.1 | 402.9 |
| IBil (μmol/L) | 241 | 66.1 | 27.2 | 134.4 | 161.6 | 8.5 | 379.3 |
| ALT (U/L) | 596 | 25 | 13 | 50.5 | 63.5 | 4 | 3160 |
| AST (U/L) | 586 | 62 | 38 | 83 | 121 | 6 | 2232 |
| GGT (U/L) | 706 | 105 | 43 | 181 | 224 | 4 | 2487 |
| ALP (U/L) | 732 | 143.5 | 100 | 107.5 | 207.5 | 43.6 | 2098 |

*The number of cases (n) counts the patients who had a pre-medication test

Table 2
Description of the pre-medication serum liver enzyme indicators (non-normal distribution)*
| Variable | Number of case | Median | Lower quartile | Interquartile range | Upper quartile | Minimum | Maximum |
|----------|----------------|--------|----------------|---------------------|---------------|---------|---------|
| TBil (μmol/L) | 549 | 69.1 | 28.2 | 146.2 | 174.4 | 5.7 | 766.6 |
| DBil (μmol/L) | 550 | 14.75 | 8 | 30.5 | 38.5 | 0.3 | 560.2 |
| IBil (μmol/L) | 62 | 43.55 | 19.8 | 72.9 | 92.7 | 10.1 | 289.9 |
| ALT(U/L) | 245 | 27 | 14 | 57 | 71 | 3 | 3160 |
| AST(U/L) | 225 | 29 | 35 | 82 | 117 | 15 | 13750 |
| GGT(U/L) | 357 | 94 | 43 | 173 | 216 | 9 | 3645 |
| ALP(U/L) | 349 | 124 | 91 | 97 | 188 | 15 | 1683 |

*The number of cases (n) counts the patients who had a post-medication test

Table 3
Description of the post-medication serum liver enzyme indicators (non-normal distribution)*

**Qualitative analysis of liver enzyme changes after the medication**

The liver enzyme changes in jaundice patients are presented in Tables 4 and 5, which show that, for most patients, the serum liver enzyme levels decreased after *yinzhihuang* granule treatment. The patients with decreased IBil and TBil levels comprised the largest percentages, 61.22% and 56.64%, respectively, of the total patients. After *yinzhihuang* granule treatment, the serum liver enzyme levels of most jaundice patients returned to normal. The patients with ALT and ALP levels normalized comprised the largest percentages, 81.93% and 79.22%, respectively, of the total patients.
Table 4
Changes of serum liver enzyme indicators after the medication: decrease/increase

| Variable   | Normal/counts | Abnormal/counts | Total   |
|------------|---------------|-----------------|---------|
| TBil (μmol/L) | 281 76.15     | 88 23.85        | 369 100 |
| DBil (μmol/L) | 268 68.37     | 124 31.63       | 392 100 |
| IBil (μmol/L) | 35 71.43      | 14 28.57        | 49 100  |
| ALT(U/L)    | 136 81.93     | 30 18.07        | 166 100 |
| AST(U/L)    | 114 72.15     | 44 27.85        | 158 100 |
| GGT(U/L)    | 177 77.63     | 51 22.37        | 228 100 |
| ALP(U/L)    | 183 79.22     | 48 20.78        | 231 100 |

Table 5
Classification of serum liver enzyme indicators after the medication: normal/abnormal

Test of the difference in liver enzyme indicators before and after the medication

Because the difference in liver enzyme indicators before and after the medication did not follow the normal distribution, we performed a non-parametric test known as Wilcoxon signed-rank, with the results
presented in Table 6, from which one sees that the average TBil, IBil, GGT, and ALP levels decreased after the yinzhihuang granule treatment. Because the P-values were all less than 0.05, the differences were statistically significant and the null hypothesis was rejected, demonstrating that the test results had a difference before and after the medication. After the yinzhihuang granule treatment, the patients’ average DBil level raised slightly and average ALT level decreased; but both P-values were greater than 0.05 (P = 0.3801 and 0.0656, respectively), indicating that the differences were not statistically significant. After the yinzhihuang granule treatment, the patients’ average AST level markedly elevated. Considering that both sets of data were not normally distributed, the mean value may be inappropriate to describe the central tendency and the use of the median value may be more reasonable. The post-medication median AST level of the jaundice patients was 29.00U/L, which was lower than that before the medication (62.00U/L). Because P = 0.0278, the difference was statistically significant.

| Variable    | Number of case(n) | Pre-medication Mean±SD | Post-medication Mean±SD | Statistics S | P value |
|-------------|-------------------|------------------------|-------------------------|--------------|---------|
| TBil(μmol/L)| 369               | 126.46±109.82          | 112.42±109.64           | 9106.5       | <0.0001 |
| DBil(μmol/L)| 392               | 43.19±62.70            | 46.96±79.43             | 1422.5       | 0.3801  |
| IBil(μmol/L)| 49                | 96.22±82.22            | 63.03±53.66             | 277          | 0.0017  |
| ALT(U/L)    | 166               | 108.87±295.46          | 91.76±282.56            | 865.5        | 0.0656  |
| AST(U/L)    | 158               | 135.55±241.51          | 200.28±986.27           | 1031.5       | 0.0278  |
|             |                   | Median=62.00           | Median=29.00            |              |         |
| GGT(U/L)    | 228               | 190.13±250.46          | 182.61±288.87           | 2872.5       | 0.0002  |
| ALP(U/L)    | 231               | 187.77±163.00          | 186.43±197.09           | 2656.5       | 0.0009  |

Table 6
Difference in the serum liver enzyme levels before and after the medication

Discussion
Effects of yinzhihuang granule on liver enzyme indicators in jaundice patients

TCM has a long history in treating jaundice. Yinzhihuang granule was derived from Yinchenhao decoction, a classic prescription in Zhongjing Zhang’s “Treatise on Febrile Diseases.” The
prescription, consisting of four Chinese medicines (Artemisiae Scopariae Herba, Scutellariae Radix, Gardeniae Fructus, Lonicerae Japonicae) [17], is used to treat jaundice caused by liver-gallbladder dampness-heat. According to TCM, the monarch drug Artemisiae Scopariae Herba is bitter, acrid, slightly cold and has the effects of clearing damp-heat, increasing choleresis, and relieving jaundice [18]; the minister drug Gardeniae Fructus is bitter, cold and has the effects of purging fire, relieving restlessness, and clearing damp-heat [19]; Scutellariae Radix is bitter, cold and has the effects of clearing away heat and dry dampness, purging fire to eliminate toxin [20]; Lonicerae Japonicae Flos is cold, tastes sweet, and has the effects of clearing heat and detoxifying, anti-inflammation [21]. The four Chinese medicines work together compatibly to play the role of clearing heat and detoxifying, clearing dampness and removing jaundice. The clinical application of yinzhihuang granules is mostly to treat neonatal jaundice [22], whose effectiveness has been verified in clearing jaundice and reducing enzyme activity. For example, some scholars demonstrated that yinzhihuang granules, when combined with intermittent blue light irradiation, can reduce the bilirubin levels in jaundice neonates [23], the GGT levels, and the ALP levels; the differences were statistically significant (P<0.05); the effectiveness and safety were both better than the sole blue light irradiation treatment [24].

The present study demonstrated that the jaundice patients’ average serum TBil, IBil, AST, GGT, and ALP levels decreased after the yinzhihuang granule treatment (P<0.05), but their ALT levels were not significantly affected. Although the ALT levels decreased by 17.11U/L, the difference was not statistically significant because P = 0.0656. After the yinzhihuang granule treatment, the average DBil level increased by 3.77μmol/L (P<0.05). This elevation might be associated with the change of the conditions of the patients, who had not yet recovered. These results, which were obtained by analyzing the existing real-world HIS data, demonstrate that yinzhihuang granules help to reduce the jaundice patients’ TBil (P<0.0001), IBil (P = 0.0017 < 0.05), AST (P = 0.0278 < 0.05), GGT (P = 0.0002 < 0.05), ALP (P = 0.0009 < 0.05) levels, but do not imply that yinzhihuang granules help to reduce the jaundice patients’ DBil (P = 0.3801 > 0.05) and ALT (P = 0.0656 > 0.05) levels.

The pharmacological mechanisms of yinzhihuang granule have not yet been completely understood due to its complex active ingredients and versatile action pathways. Modern pharmacological studies have found that the volatile oil component contained in the monarch drug Artemisiae Scopariae Herba can obviously antagonize the serum ALT and AST activities induced by carbon tetrachloride (CCl4) in mice with liver injury and can thus protect the liver from CCl4 injury [25]. By inducing the liver enzyme system, Artemisiae Scopariae Herba enhances the liver’s absorption, binding, excretion of bilirubin, and promotes the removal of bilirubin [26]. The minister drug Gardeniae Fructus may play an anti-cholestasis role by participating in biological processes such as acute inflammatory response, positive regulation of reactive oxygen metabolism, and nitric oxide anabolism [27], thereby promoting bilirubin excretion [28]. In one study, yinzhihuang granules were used to intervene estrogen-induced cholestasis in rats. After 14 days, it was found that the bile flow rate and the total bile flux increased and that the levels of ALT, AST, ALP, TBil, DBil, IBil and total bile acid (TBA) were significantly reduced [29]. The mechanism of removing jaundice and increasing choleresis may be the up-regulation of the expression of multidrug resistance transporters Mrp2 and Mrp3 in hepatocyte membrane and the enhancing of the excretion capability of hepatocytes
with cholestasis [30], thereby reducing the accumulation of bilirubin and cholate in the hepatocytes [31]. Through network pharmacology studies, some scholars found that the target of *yinzhihuang* granule aided liver disease treatment may be the epidermal growth factor receptor (EGFR). Studies have confirmed that EGFR plays an indispensable role in hepatocytes repair and regeneration and is a key regulator of the hepatocytes proliferation in the early stage of liver regeneration [32]. By promoting the proliferation of hepatocytes, EGFR plays a role in resisting liver damage [33].

Taken the present information together, *yinzhihuang* granules have the following four mechanisms to remove jaundice, protect liver, and reduce enzyme activities: (1) preventing liver injury by antagonizing the serum ALT and AST activities induced by CCl4; (2) anticholestasis, promoting bilirubin excretion and clearance; (3) up-regulating the expression of Mrp2 and Mrp3, reducing the accumulation of bilirubin; (4) promoting the proliferation, repair, regeneration of hepatocytes, thereby protecting the liver.

Although the above studies have beneficially explored from different angles the mechanisms of *yinzhihuang* granules in removing jaundice and reducing enzyme activities, more bioinformatics studies and experimental verifications are further needed to learn the mechanisms of multi-ingredient, multi-target, and multi-pathway drug action to remove jaundice and reduce enzyme activities, in consideration that the active ingredients of *yinzhihuang* granules are complex and unclear, as well as the ingredient targets.

**Real-world research based on HIS database**

As a new research field, real-world studies have received ever-increasing attentions from the broad masses of doctors, researchers, policy makers and have thus exerted profound influences upon the formulation of health policies. In 2010, Yanming Xie's research group published an article entitled “real-world research: a new idea for evaluating the effect of traditional Chinese medicine intervention measures,” which introduced the concept of real-world research to China for the first time [34]. After nearly a decade of development, China’s real-world research has made progress in the fields of post-marketing evaluation of drugs, medical insurance decision-making, and medical equipment supervision. In the field of TCM, some scholars found that the primary applications of real-world research are the effectiveness and safety evaluation of the proprietary Chinese medicines after their entering the market. Because 49.60% of the data were from HIS [35], HIS based data analysis is the main mode of real-world research in the present field of TCM. The real-world evidences obtained by the HIS based analysis makes up to certain degree the extrapolation limits of randomized controlled trial conclusions and can better evaluate the actual therapeutic effect and safety of a proprietary Chinese medicine in the practical medical environment [36]. Although the efficacy of *yinzhihuang* granules in treating jaundice has been confirmed by a number of randomized controlled trials, the questions have not been answered by relevant researches such as the actual effects of clinical application and the influence upon the liver enzyme indicators. By extracting a huge amount of data from many 3A hospitals in China, a large-scale electronic medical record integration data warehouse was established by Institute of Basic Research in Clinical
Through processes such as data cleaning and standardization, the analyzable real-world data were finally formed, which laid the groundwork for the evaluation of the safety and real-world effectiveness of yinzhihuang granules after their entering into the market. Through the analysis of HIS data by descriptive statistical method and non-parametric test (Wilcoxon sign-ranked), we obtained the actual intervention effect of yinzhihuang granules on the serum liver enzymes of jaundice patients in the real medical environment, and the results were consistent with the relevant literature. The real-world evidence obtained in this study can supplement to some degree the evidence chain of the effectiveness evaluation of yinzhihuang granules after their entering into the market, and provide reference and basis for further clinical trials and researches on pharmacological mechanisms.

However, HIS-data based real-world studies are limited by data missing and confounding factors, which reduce to some degree the accuracy of causal inference. This study only described the changes of serum liver enzyme indicators in jaundice patients, without considering the other factors that could affect the curative effect (e.g., the use of other drugs to treat jaundice may decrease the levels of serum liver enzymes); thus, the causal inference of therapeutic outcomes was not very convincing. Randomized controlled trials remained the primary means of efficacy evaluation. For the next step, the results should be verified by carrying out multicenter, randomized, double-blind, controlled trials that are of high-quality and prospective; the pharmacological mechanisms also need to be further studied. Moreover, this study was not able to evaluate the safety of treating jaundice patients with yinzhihuang granules, due to the lack of records of adverse reactions and the fact that the patients were not followed up for a certain period. Prospective, multi-center, safe hospital monitoring should also be the focus of the next step research.

**Conclusion**

Based on the existing real-world HIS data analysis, we found that yinzhihuang granules help to decrease jaundice patients’ Tbil, IBil, AST, GGT, and ALP levels; there were no evidence of yinzhihuang granules decreasing jaundice patients’ DBil and ALT levels.

**Abbreviations**

TCM: Traditional Chinese medicine; HIS: Hospital information system; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: \( \gamma \)-glutamyl transpeptidase; Tbil: Total bilirubin; DBil: Direct bilirubin; IBil: Indirect bilirubin; TBA: Total bile acid.

**Declaration**

**Ethics approval and consent to participate**

Not applicable.
Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors have no competing interests.

Funding

This work was supported by National Key R&D Program of China(2018YFC1707400).

Authors' contributions

CZ designed the analyses and wrote the first draft of the manuscript. LDZ, JL, and YMX critically reviewed the manuscript. YTX analyzed clinical data. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Yan Zhuang for the extraction of HIS data.

References

1. Li X, Yu WL, Xu S, Shi S, Zhang YJ. The animal experimental study of the function of magnesium isoglycyrrhizinate for the liver protective effect during the liver injury induced by biliary obstruction. Progress in Modern Biomedicine. 2015;15:425-8.

2. Winger J, Michelfelder A. Diagnostic approach to the patient with jaundice. Primary Care Clinics in Office Practice. 2011;38:469-82.

3. Jaundice in Adults. AM FAM Physician. 2017;95.

4. Wu MH, Wang XY. Hepatobiliary syndrome—the jaundice. In: Xiao PX, editor. TCM internal medicine (Edition 9). Beijing: China Press of Traditional Chinese Medicine; 2012. p. 250.

5. Li X, Wang XY, Wang SY. Differentiation and treatment of jaundice with reference to treatise on cold pathogenic and miscellaneous diseases and internal medicine of traditional Chinese Medicine. J
6. Cheng LH, Zhang WC. System evaluation of Yinzhihuang granules combined with blue light irradiation treating to newborn pathological jaundice. J Jiangxi Uni Tradit Chin Med. 2018; 30: 44-48.

7. Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med J. 2016; 92: 223.

8. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp Med (Lond). 2017; 78: 699-704.

9. Church RJ, Watkins PB. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials. Exp. Biol. Med. (Maywood). 2018; 243: 300-307.

10. Houlihan DD, Armstrong MJ, Newsome PN. Investigation of jaundice. Medicine. 2011; 39: 518-22.

11. Gondal B, Aronsohn A. A systematic approach to patients with jaundice. Seminars in Interventional Radiology. 2016; 33: 253-8.

12. Zhuang Y, Xie BT, Weng SX, Xie YM. Construction and realization of real world integrated data warehouse from HIS on re-evaluation of post-marketing traditional Chinese medicine. Chin J Chin Mater Med. 2011; 36: 2883-7.

13. Wan XH, Liu XF, Liu CY. The jaundice. In: Wu J, Zhang YQ, editors. Diagnostics (Edition 9). Beijing: People’s Medical Publishing House; 2018. p. 36.

14. Yang J, Li L, Xie YM, Shen H, Zhuang Y. Outcome study on parenterally administered Shenfu in treatment of coronary heart disease. Chin J Chin Mater Med. 2013; 38: 3099-103.

15. Zhang Y, Yang W, Jiang JH, Wang ZF, Li L. Impact analysis of the clinical use of shenfu injection on liver function by using propensity score methods. J Liaoning Uni Tradit Chin Med. 2016; 18: 66-70.

16. Ai QH, Xie YM, Li L, Yang W. Research on the effect of Shenqifuzheng injection on aspartate aminotransferase in real world: with propensity score analysis. J Tradit Chin Med. 2014; 55: 1596-1600.

17. Kang QW, Yan S. Progress in pharmacological action and clinical application of Yinchenhao decoction. Chin J Sur Inte Tradit Wes Med. 2013; 19: 473-5.

18. Liu YP, Qiu XY, Liu Y, Ma G. Research on pharmacological effect of Artemisiae Scopariae Herba. Chin Tradit Herbal Drugs. 2019; 50: 2235-41.

19. Shi YP, Kong HT, Li HN, Li XB, Zhang Y, Han LW, et al. Research progress on chemical composition and pharmacological effects of Gardenia jasminoides and predictive analysis on quality marker (Q-marker). Chin Tradit Herbal Drugs. 2019; 50: 281-9.

20. Wang JY. Research progress on pharmacological effects of scutellaria baicalensis Georgi. Nei Mongol J Tradit Chin Med. 2020; 39: 167-8.

21. Liu YF, Li LP, Ma HY, Zhu LJ, Sun SS, Hu YX, et al. Research progress on the chemical constituents and pharmacological effects of Lonicera Japonica Thunb. J Liaoning Uni (Nat Sci). 2018; 45: 255-62.

22. Cao M. The effect of Yinzhihuang combined blue light therapy on breast milk jaundice. J North Pharmacy. 2016; 13: 36-37.
23. Luo JQ, Rao JL. Yinzhihuang granule combined with intermittent blue light irradiation in the treatment of 42 cases of neonatal jaundice. Guangming J Chin Med. 2019;34:3644-5.
24. Ma Y, Gu L, Gao L, Gu ZY. Clinical Observation and safety analysis of blue light irradiation combined with Yindanhuang granule on neonatal jaundice. WJTCM. 2019;14:3237-40.
25. Gao Q, Zhao X, Yin L, Zhang YB, Wang B, Wu XL, et al. The essential oil of Artemisia capillaris protects against CCl4-induced liver injury in vivo. Revista Brasileira De Farmacognosia. 2016;26:369-74.
26. Ulicná O, Greksák M, Vancová O, Zlatos L, Galbavý S, Bozek P, et al. Hepatoprotective effect of rooibos tea (Aspalathus linearis) on CCl4-induced liver damage in rats. Physiol Res. 2003;52: 461-6.
27. Chen H, Gao X, Zhao W, Yu H, Wang NS, Liu HZ, et al. Mechanism of gardenia jasminoides against cholestasis based on network pharmacology. Chin J Chin Mater Med. 2019;44:2709-18.
28. Li Y, Gao XX, Qin XM. Advances in research of traditional Chinese medicine for promoting bile secretion and excretion. Chin J Chin Mater Med. 2020;45:1287-96.
29. Zhang GQ. Preliminary study on the mechanism of Yinzhihuang granule in the treatment of estrogen-induced cholestasis in rats. Lanzhou University. 2012.
30. Fardel O, Jigorel E, LeVee M, Payen L. Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed Pharmacother. 2005;59: 104.
31. Zhang GQ. Study on the cholagogic mechanism of Yinzhihuang granule based on hepatocyte membrane multidrug resistance-related transporter. 2013 China Pharmaceutical Congress and the 13th China Pharmacists week Proceedings. 2013:416-23.
32. Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. Int J Mol Sci. 2015;17:30.
33. Wang H, Xie J, He HF, Pan YM, Zhao YL. Network pharmacology study of liver disease adjuvant characteristics of Yinzhihuang granules based on correlation mechanism. Eva Anal Drug-Use Hosp Chin. 2016;16:1585-7.
34. Tian F, Xie YM. Real-world study: a potentential new approach to effectiveness evaluation of traditional Chinese medicine interventions. JIM. 2010;8:301-6.
35. Chen J, Sun Y, Bu YX, Tian JH. Analysis of real world studies on traditional Chinese medicine in China. Chin J EBM. 2018;18:1216-23.
36. Sun X, Tan J, Tang L, Li L, Wang W. Synergy between observational and experimental studies in the real-world research. Chin J EBM. 2018;18:277-83.
37. Gao MY, Xie YM, Zhang Y, Chen C, Zhuang Y. Research on clinical application of Fufangkushen injection in treating indication (therioma) in real world based on hospital information system database. Chin Tradit Herbal Drugs. 2018;49:3143-7.

Figures
Figure 1

Pre- and post-medication TBil boxplot (n=369)
Figure 2

Pre- and post-medication DBil boxplot (n=392)
Figure 3

Pre- and post-medication IBil boxplot (n=49)
Figure 4

Pre- and post-medication ALT boxplot (n=166)
Figure 5

Pre- and post-medication AST boxplot (n=158)
Figure 6

Pre- and post-medication GGT boxplot (n=228)
Figure 7

Pre- and post-medication ALP boxplot (n=231)